Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Acrocephalosyndactylia × infigratinib × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Gastrointestinal 1 Breast 1

Conditions

Urinary Bladder Neoplasms 3 Upper Tract Urothelial Carcinomas 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Lung Neoplasms 1 Acrocephalosyndactylia 1

Interventions

pemigatinib 2 pembrolizumab 1 infigratinib 1 erdafitinib 1 derazantinib 1 atezolizumab 1 Rogaratinib 1 Gemcitabine 1 Drug Combinations 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04972253 2022-08-10

(BLASST)-3

Dana-Farber Cancer Institute

Phase 1 Withdrawn

Acrocephalosyndactylia, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡